References
- Oyston P, Robinson K. The current challenges for vaccine development. J Med Microbiol [Internet]. 2012;61:889–894. Available from: http://jmm.microbiologyresearch.org/content/journal/jmm/10.1099/jmm.0.039180-0
- Ita K. Transdermal delivery of vaccines – recent progress and critical issues. Biomed Pharmacother [Internet]. 2016;83:1080–1088. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0753332216309672
- Kartoglu U, Milstien J. Tools and approaches to ensure quality of vaccines throughout the cold chain. Expert Rev Vaccines. 2014;13:843–854.
- Lebre F, Hearnden CH, Lavelle EC. Modulation of immune responses by particulate materials. Adv Mater [Internet]. 2016;28:5525–5541. Available from. .
- Zaric M, Lyubomska O, Poux C, et al. Dissolving microneedle delivery of nanoparticle-encapsulated antigen elicits efficient cross-priming and th1 immune responses by murine langerhans cells. J Invest Dermatol [Internet]. 2015;135:425–434. Available from. .
- Marshall S, Sahm LJ, Moore AC. The success of microneedle-mediated vaccine delivery into skin. Hum Vaccines Immunother [Internet]. 2016;12:2975–2983. Available from. .
- Zaric M, Lyubomska O, Touzelet O, et al. Skin dendritic cell targeting via microneedle arrays laden with antigen-encapsulated poly-D, L-Lactide-Co-Glycolide nanoparticles induces efficient antitumor and antiviral immune responses. ACS Nano. 2013;7:2042–2055.
- De Temmerman M-L, Rejman J, Demeester J, et al. Particulate vaccines: on the quest for optimal delivery and immune response. Drug Discov Today. Internet. 2011;16:569–582. cited 2014 Aug 17. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21570475
- Woodham AW, Yan L, Skeate JG, et al. T cell ignorance is bliss: T cells are not tolerized by Langerhans cells presenting human papillomavirus antigens in the absence of costimulation. Papillomavirus Res [Internet]. 2016;2:21–30. Available from: http://linkinghub.elsevier.com/retrieve/pii/S2405852115300069
- Walsh KP, Mills KH. Dendritic cells and other innate determinants of T helper cell polarisation. Trends Immunol [Internet]. 2013;34:521–530. Available from: http://linkinghub.elsevier.com/retrieve/pii/S1471490613001178
- Chen K, McAleer JP, Lin Y, et al. Th17 cells mediate clade-specific, serotype-independent mucosal immunity. Immunity [Internet]. 2011;35:997–1009. Available from: http://linkinghub.elsevier.com/retrieve/pii/S1074761311005140
- Clem AS. Fundamentals of vaccine immunology. J Glob Infect Dis [Internet]. 2011;3:73. Available from: http://www.jgid.org/text.asp?2011/3/1/73/77299
- Cohn L, Delamarre L. Dendritic cell-targeted vaccines. Front Immunol [Internet]. 2014;5:255. [cited 2014 Jul 10]. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4039009&tool=pmcentrez&rendertype=abstract
- WHO. Injection safety policy and global campaign. Geneva, Switzerland: WHO; 2016.
- Taddio A, Ipp M, Thivakaran S, et al. Survey of the prevalence of immunization non-compliance due to needle fears in children and adults. Vaccine [Internet]. 2012;30:4807–4812. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0264410X1200686X
- Nir Y, Paz A, Sabo E, et al. Fear of injections in young adults: prevalence and associations. Am J Trop Med Hyg. 2003;68:341–344.
- Arya J, Prausnitz MR. Microneedle patches for vaccination in developing countries. J Control Release [Internet]. 2016;240:135–141. Available from: http://linkinghub.elsevier.com/retrieve/pii/S016836591530242X
- Cordeiro AS, Alonso MJ, De La Fuente M. Nanoengineering of vaccines using natural polysaccharides. Biotechnol Adv [Internet]. 2015;33:1279–1293. Available from. .
- Lee S, Nguyen MT. Recent advances of vaccine adjuvants for infectious diseases. Immune Netw [Internet]. 2015;15:51. Available from: https://synapse.koreamed.org/DOIx.php?id=10.4110/in.2015.15.2.51
- Awate S, Babiuk LA, Mutwiri G. Mechanisms of action of adjuvants. Front Immunol [Internet]. 2013;4:114. Available from: http://journal.frontiersin.org/article/10.3389/fimmu.2013.00114/abstract
- Di Pasquale A, Preiss S, Silva F, et al. Vaccine adjuvants: from 1920 to 2015 and beyond. Vaccines [Internet]. 2015;3:320–343. Available from: http://www.mdpi.com/2076-393X/3/2/320/
- Boraschi D, Italiani P. From antigen delivery system to adjuvanticy: the board application of nanoparticles in vaccinology. Vaccines [Internet]. 2015;3:930–939. Available from: http://www.mdpi.com/2076-393X/3/4/930/
- Oleszycka E, Mccluskey S, Sharp FA, et al. The vaccine adjuvant alum promotes IL-10 production that suppresses Th1 responses. Eur J Immunol [Internet]. 2018;1–11. Available from: http://doi.wiley.com/10.1002/eji.201747150
- Jacobson RM, Swan A, Adegbenro A, et al. Making vaccines more acceptable — methods to prevent and minimize pain and other common adverse events associated with vaccines. Vaccine [Internet]. 2001;19:2418–2427. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0264410X00004667
- Elamanchili P, Lutsiak CM, Hamdy S, et al. pathogen-mimicking” nanoparticles for vaccine delivery to dendritic cells. J Immunother [Internet]. 2007;30:378–395. Available from: http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00002371-200705000-00003
- Apostolopoulos V, Thalhammer T, Tzakos AG, et al. Targeting antigens to dendritic cell receptors for vaccine development. J Drug Deliv [Internet]. 2013;2013:869718. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3817681&tool=pmcentrez&rendertype=abstract
- Abd-El-Aziz AS, Abdelghani AA, El-Sadany SK, et al. Antimicrobial and anticancer activities of organoiron melamine dendrimers capped with piperazine moieties. Eur Polym J [Internet]. 2016;82:307–323. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0014305716301938
- Niikura K, Matsunaga T, Suzuki T, et al. Gold nanoparticles as a vaccine platform: influence of size and shape on immunological responses in vitro and in vivo. ACS Nano [Internet]. 2013;7:3926–3938. Available from: http://pubs.acs.org/doi/10.1021/nn3057005
- Bibi S, Kaur R, Henriksen-Lacey M, et al. Microscopy imaging of liposomes: from coverslips to environmental SEM. Int J Pharm [Internet]. 2011;417:138–150. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0378517310009622
- Li S, Li H, Wang X, et al. Super-hydrophobicity of large-area honeycomb-like aligned carbon nanotubes. J Phys Chem B [Internet]. 2002;106:9274–9276. Available from: http://pubs.acs.org/doi/abs/10.1021/jp0209401
- Gutjahr A, Phelip C, Coolen A-L, et al. Biodegradable polymeric nanoparticles-based vaccine adjuvants for lymph nodes targeting. Vaccines. 2016;4:34.
- Manolova V, Flace A, Bauer M, et al. Nanoparticles target distinct dendritic cell populations according to their size. Eur J Immunol [Internet]. 2008;38:1404–1413. Available from. .
- Petrizzo A, Conte C, Tagliamonte M, et al. Functional characterization of biodegradable nanoparticles as antigen delivery system. J Exp Clin Cancer Res [Internet]. 2015;34:114. Available from: http://www.jeccr.com/content/34/1/114
- Joshi VB, Geary SM, Salem AK. Biodegradable particles as vaccine delivery systems: size matters. AAPS J [Internet]. 2013;15:85–94. Available from. .
- Jia J, Zhang W, Liu Q, et al. Adjuvanticity regulation by biodegradable polymeric nano/microparticle size. Mol Pharm [Internet]. 2017;14:14–22. Available from. .
- Newman KD, Elamanchili P, Kwon GS, et al. Uptake of poly(D,L-lactic-co-glycolic acid) microspheres by antigen-presenting cells in vivo. J Biomed Mater Res [Internet]. 2002;60:480–486. Available from. .
- Sharma G, Valenta DT, Altman Y, et al. Polymer particle shape independently influences binding and internalization by macrophages. J Control Release [Internet]. 2010;147:408–412. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0168365910006437
- Cruz LJ, Rosalia RA, Kleinovink JW, et al. Targeting nanoparticles to CD40, DEC-205 or CD11c molecules on dendritic cells for efficient CD8+ T cell response: A comparative study. J Control Release [Internet]. 2014;192:209–218. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0168365914005215
- Tamayo I, Irache JM, Mansilla C, et al. Poly(Anhydride) nanoparticles act as active th1 adjuvants through toll-like receptor exploitation. Clin Vaccine Immunol [Internet]. 2010;17:1356–1362. Available from: http://cvi.asm.org/cgi/doi/10.1128/CVI.00164-10
- Sharp FA, Ruane D, Claass B, et al. Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome. Proc Natl Acad Sci. 2009;106:870–875.
- Gutjahr A, Tiraby G, Perouzel E, et al. Triggering intracellular receptors for vaccine adjuvantation. Trends Immunol [Internet]. 2016;37:573–587. Available from.
- Margaroni M, Agallou M, Kontonikola K, et al. PLGA nanoparticles modified with a TNFα mimicking peptide, soluble Leishmania antigens and MPLA induce T cell priming in vitro via dendritic cell functional differentiation. Eur J Pharm Biopharm [Internet]. 2016;105:18–31. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0939641116301837
- Ebrahimian M, Hashemi M, Maleki M, et al. Co-delivery of dual toll-like receptor agonists and antigen in poly(lactic-co-glycolic) acid/polyethylenimine cationic hybrid nanoparticles promote efficient in vivo immune responses. Front Immunol [Internet]. 2017;8:1077. Available from: http://journal.frontiersin.org/article/10.3389/fimmu.2017.01077/full
- Villena J, Medina M, Racedo S, et al. Resistance of Young Mice to Pneumococcal infection can be improved by oral vaccination with recombinant lactococcus lactis. J Microbiol Immunol Infect [Internet]. 2010;43:1–10. Available from: http://linkinghub.elsevier.com/retrieve/pii/S1684118210600011
- Arulanandam B, Lynch J, Briles D, et al. Intranasal vaccination with pneumococcal surface protein a and interleukin-12 augments antibody-mediated opsonization and protective immunity against streptococcus pneumoniae infection. Infect Immun [Internet]. 2001;69:6718–6724. Available from. .
- Song J-H, Nguyen HH, Cuburu N, et al. Sublingual vaccination with influenza virus protects mice against lethal viral infection. Proc Natl Acad Sci [Internet]. 2008;105:1644–1649. Available from. .
- Rouphael NG, Paine M, Mosley R, et al. The safety, immunogenicity, and acceptability of inactivated influenza vaccine delivered by microneedle patch (TIV-MNP 2015): a randomised, partly blinded, placebo-controlled, phase 1 trial. Lancet [Internet]. 2017;390:649–658. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0140673617305755
- Mitragotri S. Immunization without needles. Nat Rev Immunol [Internet]. 2005;5:905–916. Available from: http://www.nature.com/articles/nri1728
- Baroli B. Penetration of nanoparticles and nanomaterials in the skin: fiction or reality? J Pharm Sci [Internet]. 2010;99:21–50. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0022354916303434
- Jepps OG, Dancik Y, Anissimov YG, et al. Modeling the human skin barrier — towards a better understanding of dermal absorption. Adv Drug Deliv Rev [Internet]. 2013;65:152–168. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0169409X12001226
- Al-Zahrani S, Zaric M, McCrudden CM, et al. Microneedle-mediated vaccine delivery: harnessing cutaneous immunobiology to improve efficacy. Expert Opin Drug Deliv [Internet]. 2012;9:541–550. Available from: http://www.tandfonline.com/doi/full/10.1517/17425247.2012.676038
- Romani N, Flacher V, Tripp CH, et al. Targeting skin dendritic cells to improve intradermal vaccination. Curr Top Microbiol Immunol [Internet] Europe PMC Funders. 2011;113–138. Available from: http://link.springer.com/10.1007/82_2010_118
- Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nat [Internet]. 2007;449:419–426. Available from: http://www.nature.com/articles/nature06175
- Zhao Z, Ukidve A, Dasgupta A, et al. Transdermal immunomodulation: principles, advances and perspectives. Adv Drug Deliv Rev [Internet]. 2018;127:3–19. Available from. .
- Godefroy S, Peyre M, Garcia N, et al. Effect of skin barrier disruption on immune responses to topically applied cross-reacting material, CRM197, of diphtheria toxin. Infect Immun [Internet]. 2005;73:4803–4809. Available from: http://iai.asm.org/cgi/doi/10.1128/IAI.73.8.4803-4809.2005
- Weber CS, Hainz K, Deressa T, et al. Immune reactions against gene gun vaccines are differentially modulated by distinct dendritic cell subsets in the skin. Haziot A, editor. PLoS One [Internet]. 2015;10:e0128722. Available from. .
- Paudel KS, Milewski M, Swadley CL, et al. Challenges and opportunities in dermal/transdermal delivery. Ther Deliv [Internet]. 2010;1:109–131. Available from: http://www.future-science.com/doi/10.4155/tde.10.16
- Alkilani AZ, McCrudden MT, Donnelly RF. Transdermal drug delivery: innovative pharmaceutical developments based on disruption of the barrier properties of the stratum corneum. Pharmaceutics. 2015;7:438–470.
- Donnelly RF, Majithiya R, Singh TR, et al. Design, optimization and characterisation of polymeric microneedle arrays prepared by a novel laser-based micromoulding technique. Pharm Res [Internet]. 2011;28:41–57. Available from: http://link.springer.com/10.1007/s11095-010-0169-8
- Haq MI, Smith E, John DN, et al. Clinical administration of microneedles: skin puncture, pain and sensation. Biomed Microdevices [Internet]. 2009;11:35–47. Available from: http://link.springer.com/10.1007/s10544-008-9208-1
- Quinn HL, Kearney M-C, Courtenay AJ, et al. The role of microneedles for drug and vaccine delivery. Expert Opin Drug Deliv [Internet]. 2014;11:1769–1780. Available from: http://www.tandfonline.com/doi/full/10.1517/17425247.2014.938635
- Leone M, Mönkäre J, Bouwstra JA, et al. Dissolving microneedle patches for dermal vaccination. Pharm Res [Internet]. 2017;34:2223–2240. Available from: http://link.springer.com/10.1007/s11095-017-2223-2
- González-Vázquez P, Larrañeta E, McCrudden MT, et al. Transdermal delivery of gentamicin using dissolving microneedle arrays for potential treatment of neonatal sepsis. J Control Release [Internet]. 2017;265:30–40. Available from. .
- Caffarel-Salvador E, Brady AJ, Eltayib E, et al. Hydrogel-forming microneedle arrays allow detection of drugs and glucose in vivo: potential for use in diagnosis and therapeutic drug monitoring. Chan C, editor. PLoS One [Internet]. 2015;10:e0145644. Available from.
- Larrañeta E, Lutton RE, Woolfson AD, et al. Microneedle arrays as transdermal and intradermal drug delivery systems: materials science, manufacture and commercial development. Mater Sci Eng R Reports [Internet]. 2016;104:1–32. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0927796X16300213
- Wei-Ze L, Mei-Rong H, Jian-Ping Z, et al. Super-short solid silicon microneedles for transdermal drug delivery applications. Int J Pharm [Internet]. 2010;389:122–129. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0378517310000578
- Martanto W, Davis SP, Holiday NR, et al. Transdermal delivery of insulin using microneedles in vivo. Pharm Res [Internet]. 2004;21:947–952. Available from: http://link.springer.com/10.1023/B:PHAM.0000029282.44140.2e
- Deng Y, Chen J, Zhao Y, et al. Transdermal delivery of siRNA through Microneedle Array. Sci Rep [Internet]. 2016;6:21422. Available from: http://www.nature.com/articles/srep21422
- D V M, Wang PM, Davis SP, et al. Microfabricated needles for transdermal delivery of macromolecules and nanoparticles: fabrication methods and transport studies. Proc Natl Acad Sci [Internet]. 2003;100:13755–13760. Available from. .
- Ding Z, Van Riet E, Romeijn S, et al. Immune modulation by adjuvants combined with diphtheria toxoid administered topically in BALB/c Mice after microneedle array pretreatment. Pharm Res [Internet]. 2009;26:1635–1643. Available from. .
- Gill HS, Prausnitz MR. Coated microneedles for transdermal delivery. J Control Release [Internet]. 2007;117:227–237. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0168365906005839
- Kim Y-C, Quan F-S, Compans RW, et al. Formulation and coating of microneedles with inactivated influenza virus to improve vaccine stability and immunogenicity. J Control Release [Internet]. 2010;142:187–195. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0168365909007081
- Gill H, Söderholm J, Prausnitz MR, et al. Cutaneous vaccination using microneedles coated with hepatitis C DNA vaccine. Gene Ther [Internet]. 2010;17:811–814. Available from: http://www.nature.com/articles/gt201022
- Kim Y-C, Park J-H, Prausnitz MR. Microneedles for drug and vaccine delivery. Adv Drug Deliv Rev [Internet]. 2012;64:1547–1568. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0169409X12001251
- Van Damme P, Oosterhuis-Kafeja F, Van Der Wielen M, et al. Safety and efficacy of a novel microneedle device for dose sparing intradermal influenza vaccination in healthy adults. Vaccine [Internet]. 2009;27:454–459. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0264410X08014515
- Tuan-Mahmood TM, McCrudden MT, Torrisi BM, et al. Microneedles for intradermal and transdermal drug delivery. Eur J Pharm Sci [Internet]. 2013;50:623–637. Available from.
- Donnelly RF, Singh TRR, Morrow DI, et al. Microneedle-mediated transdermal and intradermal drug delivery. Chichester, UK: John Wiley & Sons; 2012.
- Kim Y-C, Prausnitz MR. Enabling skin vaccination using new delivery technologies. Drug Deliv Transl Res [Internet]. 2011;1:7–12. Available from: http://link.springer.com/10.1007/s13346-010-0005-z
- Ito Y, Hirono M, Fukushima K, et al. Two-layered dissolving microneedles formulated with intermediate-acting insulin. Int J Pharm [Internet]. 2012;436:387–393. Available from: http://linkinghub.elsevier.com/retrieve/pii/S037851731200645X
- Donnelly RF, McCrudden MT, Alkilani AZ, et al. Hydrogel-forming microneedles prepared from “super swelling” polymers combined with lyophilised wafers for transdermal drug delivery. PLoS One. 2014;9(10):e111547.
- Garland MJ, Singh TRR, Woolfson AD, et al. Electrically enhanced solute permeation across poly(ethylene glycol)–crosslinked poly(methyl vinyl ether-co-maleic acid) hydrogels: effect of hydrogel crosslink density and ionic conductivity. Int J Pharm [Internet]. 2011;406:91–98. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0378517311000093
- Donnelly RF, Thakur RRS, Garland MJ, et al. Hydrogel-forming microneedle arrays for enhanced transdermal drug delivery. Adv Funct Mater. 2012;22:4879–4890.
- Sullivan SP, Koutsonanos DG, Del Pilar Martin M, et al. Dissolving polymer microneedle patches for influenza vaccination. Nat Med [Internet]. 2010;16:915–920. Available from: http://www.nature.com/articles/nm.2182
- Raphael AP, Prow TW, Crichton ML, et al. Targeted, needle-free vaccinations in skin using multilayered, densely-packed dissolving microprojection arrays. Small [Internet]. 2010;6:1785–1793. Available from.
- McCrudden MT, Torrisi BM, Al-Zahrani S, et al. Laser-engineered dissolving microneedle arrays for protein delivery: potential for enhanced intradermal vaccination. J Pharm Pharmacol. 2015;67:409–425.
- Hsueh K-J, Chen M-C, Cheng L-T, et al. Transcutaneous immunization of Streptococcus suis bacterin using dissolving microneedles. Comp Immunol Microbiol Infect Dis [Internet]. 2017;50:78–87. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0147957116301229
- Esser ES, Romanyuk A, E V V, et al. Tetanus vaccination with a dissolving microneedle patch confers protective immune responses in pregnancy. J Control Release [Internet]. 2016;236:47–56. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0168365916303935
- Arya J, Henry S, Kalluri H, et al. Tolerability, usability and acceptability of dissolving microneedle patch administration in human subjects. Biomater [Internet]. 2017;128:1–7. Available from: http://linkinghub.elsevier.com/retrieve/pii/S014296121730128X
- Hirobe S, Azukizawa H, Matsuo K, et al. Development and clinical study of a self-dissolving microneedle patch for transcutaneous immunization device. Pharm Res [Internet]. 2013;30:2664–2674. Available from: http://link.springer.com/10.1007/s11095-013-1092-6
- Hirobe S, Azukizawa H, Hanafusa T, et al. Clinical study and stability assessment of a novel transcutaneous influenza vaccination using a dissolving microneedle patch. Biomater [Internet]. 2015;57:50–58. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0142961215003543
- Donnelly RF, Woolfson AD. Patient safety and beyond: what should we expect from microneedle arrays in the transdermal delivery arena? Ther. Deliv. 2014;5:653–662.
- Donnelly RF. How can microneedles overcome challenges facing transdermal drug delivery? Ther. Deliv. 2017;8:725–728.
- Prausnitz MR. Engineering microneedle patches for vaccination and drug delivery to skin. Annu Rev Chem Biomol Eng [Internet]. 2017;8:9.1–9.24. Available from: http://www.annualreviews.org/doi/10.1146/annurev-chembioeng-060816-101514
- Sarti F, Perera G, Hintzen F, et al. In vivo evidence of oral vaccination with PLGA nanoparticles containing the immunostimulant monophosphoryl lipid A. Biomater [Internet]. 2011;32:4052–4057. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0142961211001633
- Rauta PR, Nayak B. Parenteral immunization of PLA/PLGA nanoparticle encapsulating outer membrane protein (Omp) from Aeromonas hydrophila: evaluation of immunostimulatory action in Labeo rohita (rohu). Fish Shellfish Immunol [Internet]. 2015;44:287–294. Available from: http://linkinghub.elsevier.com/retrieve/pii/S1050464815000601
- Alvarez-Román R, Naik A, Kalia Y, et al. Skin penetration and distribution of polymeric nanoparticles. J Control Release [Internet]. 2004;99:53–62. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0168365904002858
- Schneider M, Stracke F, Hansen S, et al. Nanoparticles and their interactions with the dermal barrier. Dermatoendocrinol. 2009;1:197–206.
- Zhang W, Gao J, Zhu Q, et al. Penetration and distribution of PLGA nanoparticles in the human skin treated with microneedles. Int J Pharm [Internet]. 2010;402:205–212. Available from: http://linkinghub.elsevier.com/retrieve/pii/S037851731000757X
- Coulman SA, Anstey A, Gateley C, et al. Microneedle mediated delivery of nanoparticles into human skin. Int J Pharm [Internet]. 2009;366:190–200. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0378517308006054
- Vora LK, Donnelly RF, Larrañeta E, et al. Novel bilayer dissolving microneedle arrays with concentrated PLGA nano-microparticles for targeted intradermal delivery: proof of concept. J Control Release [Internet]. 2017;0–1. Available from: http://www.sciencedirect.com/science/article/pii/S0168365917308921
- Ali AA, McCrudden CM, McCaffrey J, et al. DNA vaccination for cervical cancer; a novel technology platform of RALA mediated gene delivery via polymeric microneedles. nanomedicine nanotechnology. Biol Med [Internet]. 2017;13:921–932. Available from. .
- Wang C, Ye Y, Hochu GM, et al. Enhanced cancer immunotherapy by microneedle patch-assisted delivery of anti-PD1 antibody. Nano Lett. 2016;16:2334–2340.
- Carroll EC, Jin L, Mori A, et al. The vaccine adjuvant chitosan promotes cellular immunity via DNA Sensor cGAS-STING-dependent induction of type i interferons. Immunity. 2016;44:597–608.
- Vandamme K, Melkebeek V, Cox E, et al. Influence of polymer hydrolysis on adjuvant effect of Gantrez®AN nanoparticles: implications for oral vaccination. Eur J Pharm Biopharm [Internet]. 2011;79:392–398. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0939641111001652
- Martinez D, Vermeulen M, Von Euw E, et al. Extracellular acidosis triggers the maturation of human dendritic cells and the production of IL-12. J Immunol [Internet]. 2007;179:1950–1959. Available from: http://www.jimmunol.org/cgi/doi/10.4049/jimmunol.179.3.1950
- Vermeulen M, Giordano M, Trevani AS, et al. Acidosis improves uptake of antigens and MHC class I-restricted presentation by dendritic cells. J Immunol [Internet]. 2004;172:3196–3204. Available from: http://www.jimmunol.org/cgi/doi/10.4049/jimmunol.172.5.3196
- Shakya AK, Kumar A, Nandakumar KS. Adjuvant properties of a biocompatible thermo-responsive polymer of N-isopropylacrylamide in autoimmunity and arthritis. J R Soc Interface [Internet]. 2011;8:1748–1759. Available from: http://rsif.royalsocietypublishing.org/cgi/doi/10.1098/rsif.2011.0114
- Weldon WC, Zarnitsyn VG, Esser ES, et al. Effect of adjuvants on responses to skin immunization by microneedles coated with influenza subunit vaccine. Rodrigues MM, editor. PLoS One [Internet]. 2012;7:e41501. Available from.
- Van Der Maaden K, Varypataki EM, Yu H, et al. Parameter optimization toward optimal microneedle-based dermal vaccination. Eur J Pharm Sci [Internet]. 2014;64:18–25. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0928098714003133
- Depelsenaire AC, Meliga SC, McNeilly CL, et al. Colocalization of cell death with antigen deposition in skin enhances vaccine immunogenicity. J Invest Dermatol [Internet]. 2014;134:2361–2370. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0022202X15369876
- Bal SM, Ding Z, Kersten GFA, et al. Microneedle-based transcutaneous immunisation in mice with n-trimethyl chitosan adjuvanted diphtheria toxoid formulations. Pharm Res. 2010;27:1837–1847.
- Bal SM, Slütter B, Jiskoot W, et al. Small is beautiful: N-trimethyl chitosan-ovalbumin conjugates for microneedle-based transcutaneous immunisation. Vaccine [Internet]. 2011;29:4025–4032. Available from.
- Kumar A, Wonganan P, Sandoval MA, et al. Microneedle-mediated transcutaneous immunization with plasmid DNA coated on cationic PLGA nanoparticles. J Control Release [Internet]. 2012;163:230–239. Available from.
- Kumar A, Li X, Sandoval MA, et al. Permeation of antigen protein-conjugated nanoparticles and live bacteria through microneedle-treated mouse skin. Int J Nanomedicine. 2011;6:1253–1264.
- Yin D, Liang W, Xing S, et al. Hepatitis B DNA vaccine-polycation nano-complexes enhancing immune response by percutaneous administration with microneedle. Biol Pharm Bull. 2013;36:1283–1291. Internet. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23676787
- Hu Y, Xu B, Xu J, et al. Microneedle-assisted dendritic cell-targeted nanoparticles for transcutaneous DNA immunization. Polym Chem [Internet]. 2015;6:373–379. Available from: http://xlink.rsc.org/?DOI=C4PY01394H
- Seok H, Noh JY, Lee DY, et al. Effective humoral immune response from a H1N1 DNA vaccine delivered to the skin by microneedles coated with PLGA-based cationic nanoparticles. J Control Release [Internet]. 2017;265:66–74. Available from.
- Du G, Hathout RM, Nasr M, et al. Intradermal vaccination with hollow microneedles: a comparative study of various protein antigen and adjuvant encapsulated nanoparticles. J Control Release [Internet]. 2017;266:109–118. Available from.
- Siddhapura K, Harde H, Jain S. Immunostimulatory effect of tetanus toxoid loaded chitosan nanoparticles following microneedles assisted immunization. Nanomedicine Nanotechnology. Biol Med [Internet]. 2015;12:213–222. Available from: http://www.sciencedirect.com/science/article/pii/S1549963415001999
- Ripolin A, Quinn J, Larrañeta E, et al. Successful application of large microneedle patches by human volunteers. Int J Pharm [Internet]. 2017;521:92–101. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0378517317300923